PROCEPT BioRobotics Corporation Announces Pricing of Upsized Offering of Common Stock
01 Agosto 2023 - 9:10PM
PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT
BioRobotics”), a surgical robotics company focused on advancing
patient care by developing transformative solutions in urology,
today announced the pricing of an upsized underwritten public
offering of 4,422,169 shares of its common stock at a public
offering price of $33.92 per share, before underwriting discounts
and commissions, for aggregate gross proceeds of approximately $150
million. In addition, PROCEPT BioRobotics has granted the
underwriters a 30-day option to purchase up to an additional
663,325 shares of its common stock at the public offering price,
less underwriting discounts and commissions. All of the shares in
the offering are to be sold by PROCEPT BioRobotics. The offering is
expected to close on or about August 4, 2023, subject to customary
closing conditions.
BofA Securities, Piper Sandler and TD Cowen are
acting as joint book-running managers for the proposed offering.
Truist Securities is acting as co-manager.
The securities are being offered pursuant to an
effective shelf registration statement that was filed with the U.S.
Securities and Exchange Commission (the “SEC”) on August 1, 2023.
This offering is being made only by means of a prospectus
supplement and the accompanying prospectus which forms a part of
the effective shelf registration statement.
A preliminary prospectus supplement related to
the offering (including the accompanying prospectus) has been filed
with the SEC and is available on the SEC’s website located at
www.sec.gov. A final prospectus supplement related to the offering
(including the accompanying prospectus) will be filed with the SEC.
Copies of the preliminary prospectus supplement and the final
prospectus supplement, when available, and the accompanying
prospectus may also be obtained, from BofA Securities,
NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001,
Attn: Prospectus Department, or via email:
dg.prospectus_requests@bofa.com; from Piper Sandler & Co., 800
Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, Attention:
Prospectus Department, by telephone at (800) 747-3924, or via
e-mail at prospectus@psc.com; and from Cowen and Company, LLC, 599
Lexington Avenue, New York, New York 10022, by telephone at (833)
297-2926, or via e-mail at Prospectus_ECM@cowen.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy nor shall there be
any sale of these securities in any state or other jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About PROCEPT BioRobotics
CorporationPROCEPT BioRobotics is a surgical robotics
company focused on advancing patient care by developing
transformative solutions in urology. PROCEPT BioRobotics develops,
manufactures and sells the AquaBeam Robotic System, an advanced,
image-guided, surgical robotic system for use in minimally invasive
urologic surgery with an initial focus on treating benign prostatic
hyperplasia, or BPH. BPH is the most common prostate disease and
impacts approximately 40 million men in the United States. PROCEPT
BioRobotics designed Aquablation therapy to deliver effective, safe
and durable outcomes for males suffering from lower urinary tract
symptoms, or LUTS, due to BPH that are independent of prostate size
and shape or surgeon experience. PROCEPT BioRobotics has developed
a significant and growing body of clinical evidence, which includes
nine clinical studies and approximately 150 peer-reviewed
publications, supporting the benefits and clinical advantages of
Aquablation therapy.
Forward Looking StatementsThis
press release contains forward-looking statements. All statements
other than statements of historical facts contained herein,
including without limitation statements regarding the expected
closing of the public offering are forward-looking statements
reflecting the current beliefs and expectations of PROCEPT
BioRobotics’s management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements represent PROCEPT BioRobotics’s current
expectations regarding future events and are subject to known and
unknown risks and uncertainties that could cause actual results to
differ materially from those implied by the forward-looking
statements. Among those risks and uncertainties are market
conditions, including market interest rates, the trading price and
volatility of PROCEPT BioRobotics’s common stock, and risks
relating to PROCEPT BioRobotics’s business, including those risks
described in periodic reports that PROCEPT BioRobotics files from
time to time with the SEC, as well as the preliminary prospectus
supplement and accompanying prospectus relating to the offering.
The forward-looking statements included in this press release speak
only as of the date of this press release, and PROCEPT BioRobotics
does not undertake to update the statements included in this press
release for subsequent developments, except as may be required by
law.
Investor Contact:Matt Bacso, CFAVP, Investor
Relations and Business
Operationsm.bacso@procept-biorobotics.com
PROCEPT BioRobotics (NASDAQ:PRCT)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
PROCEPT BioRobotics (NASDAQ:PRCT)
Gráfica de Acción Histórica
De May 2023 a May 2024